AstraZeneca raises FY core EPS view to up low double digits to low teens

Total Revenue is expected to increase by a mid single-digit percentage (previously low-to-mid single-digit). Excluding COVID-19 medicines, Total Revenue is expected to increase by a low-teens percentage (previously low double-digit). Core EPS is expected to increase by a low double-digit to low-teens percentage (previously high single-digit to low double-digit).